642 related articles for article (PubMed ID: 24445558)
21. Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
Hartl C; Obermeier V; Gerdes LA; Brügel M; von Kries R; Kümpfel T
J Neurol Sci; 2017 Apr; 375():160-164. PubMed ID: 28320120
[TBL] [Abstract][Full Text] [Related]
22. Does vitamin D deficiency predict early conversion of clinically isolated syndrome? A preliminary Egyptian study.
Shaheen HA; Sayed SS; Daker LI; AbdelAziz HE; Taha MA
Int J Neurosci; 2018 Oct; 128(10):946-951. PubMed ID: 29493311
[TBL] [Abstract][Full Text] [Related]
23. Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis.
Wesnes K; Myhr KM; Riise T; Kvistad SS; Torkildsen Ø; Wergeland S; Holmøy T; Midgard R; Bru A; Edland A; Eikeland R; Gosal S; Harbo HF; Kleveland G; Sørenes YS; Øksendal N; Bjørnevik K
Mult Scler Relat Disord; 2021 May; 50():102801. PubMed ID: 33636616
[TBL] [Abstract][Full Text] [Related]
24. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
[TBL] [Abstract][Full Text] [Related]
25. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
Uher T; Horakova D; Kalincik T; Bergsland N; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
Eur J Neurol; 2015 Jul; 22(7):1113-23. PubMed ID: 25904020
[TBL] [Abstract][Full Text] [Related]
26. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial.
Kampman MT; Steffensen LH; Mellgren SI; Jørgensen L
Mult Scler; 2012 Aug; 18(8):1144-51. PubMed ID: 22354743
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
Mowry EM; Waubant E; McCulloch CE; Okuda DT; Evangelista AA; Lincoln RR; Gourraud PA; Brenneman D; Owen MC; Qualley P; Bucci M; Hauser SL; Pelletier D
Ann Neurol; 2012 Aug; 72(2):234-40. PubMed ID: 22926855
[TBL] [Abstract][Full Text] [Related]
28. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis.
Behrens JR; Rasche L; Gieß RM; Pfuhl C; Wakonig K; Freitag E; Deuschle K; Bellmann-Strobl J; Paul F; Ruprecht K; Dörr J
Eur J Neurol; 2016 Jan; 23(1):62-7. PubMed ID: 26220765
[TBL] [Abstract][Full Text] [Related]
29. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
[TBL] [Abstract][Full Text] [Related]
30. Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal.
Bettencourt A; Boleixa D; Reguengo H; Samões R; Santos E; Oliveira JC; Silva B; Costa PP; da Silva AM
J Steroid Biochem Mol Biol; 2018 Jun; 180():137-141. PubMed ID: 28951256
[TBL] [Abstract][Full Text] [Related]
31. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
Simon JH; Kinkel RP; Kollman C; O'Connor P; Fisher E; You X; Hyde R;
Mult Scler; 2015 Apr; 21(4):415-22. PubMed ID: 25344370
[TBL] [Abstract][Full Text] [Related]
32. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.
Freedman MS; Metzig C; Kappos L; Polman CH; Edan G; Hartung HP; Miller DH; Montalban X; Yarden J; Spector L; Fire E; Dotan N; Schwenke S; Lanius V; Sandbrink R; Pohl C
Mult Scler; 2012 Jul; 18(7):966-73. PubMed ID: 22183938
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.
Burton JM; Kimball S; Vieth R; Bar-Or A; Dosch HM; Cheung R; Gagne D; D'Souza C; Ursell M; O'Connor P
Neurology; 2010 Jun; 74(23):1852-9. PubMed ID: 20427749
[TBL] [Abstract][Full Text] [Related]
35. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.
Kalincik T; Vaneckova M; Tyblova M; Krasensky J; Seidl Z; Havrdova E; Horakova D
PLoS One; 2012; 7(11):e50101. PubMed ID: 23166826
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D and MRI measures in progressive multiple sclerosis.
Abbatemarco JR; Fox RJ; Li H; Ontaneda D
Mult Scler Relat Disord; 2019 Oct; 35():276-282. PubMed ID: 31445221
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia.
van der Mei IA; Ponsonby AL; Dwyer T; Blizzard L; Taylor BV; Kilpatrick T; Butzkueven H; McMichael AJ
J Neurol; 2007 May; 254(5):581-90. PubMed ID: 17426912
[TBL] [Abstract][Full Text] [Related]
39. Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Fitzgerald KC; Munger KL; Hartung HP; Freedman MS; Montalbán X; Edan G; Wicklein EM; Radue EW; Kappos L; Pohl C; Ascherio A;
Ann Neurol; 2017 Jul; 82(1):20-29. PubMed ID: 28556498
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
Hiremath GS; Cettomai D; Baynes M; Ratchford JN; Newsome S; Harrison D; Kerr D; Greenberg BM; Calabresi PA
Mult Scler; 2009 Jun; 15(6):735-40. PubMed ID: 19383644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
